Novo Nordisk A/S (NYSE:NVO) Shares Sold by Ledyard National Bank

Ledyard National Bank trimmed its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 2.2% during the second quarter, Holdings Channel reports. The firm owned 152,708 shares of the company’s stock after selling 3,422 shares during the period. Novo Nordisk A/S comprises about 1.0% of Ledyard National Bank’s holdings, making the stock its 23rd largest position. Ledyard National Bank’s holdings in Novo Nordisk A/S were worth $7,794,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in NVO. Creative Planning grew its holdings in Novo Nordisk A/S by 32.8% in the 2nd quarter. Creative Planning now owns 35,379 shares of the company’s stock worth $1,806,000 after buying an additional 8,740 shares in the last quarter. JNBA Financial Advisors boosted its stake in Novo Nordisk A/S by 11.3% during the 2nd quarter. JNBA Financial Advisors now owns 6,372 shares of the company’s stock valued at $325,000 after purchasing an additional 645 shares in the last quarter. Ballentine Partners LLC boosted its stake in Novo Nordisk A/S by 16.6% during the 2nd quarter. Ballentine Partners LLC now owns 8,421 shares of the company’s stock valued at $430,000 after purchasing an additional 1,201 shares in the last quarter. Wetherby Asset Management Inc. boosted its stake in Novo Nordisk A/S by 3.6% during the 2nd quarter. Wetherby Asset Management Inc. now owns 33,659 shares of the company’s stock valued at $1,718,000 after purchasing an additional 1,162 shares in the last quarter. Finally, Squar Milner Financial Services LLC boosted its stake in Novo Nordisk A/S by 11.4% during the 2nd quarter. Squar Milner Financial Services LLC now owns 10,093 shares of the company’s stock valued at $515,000 after purchasing an additional 1,031 shares in the last quarter. Institutional investors and hedge funds own 7.12% of the company’s stock.

A number of equities analysts have issued reports on the company. Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 price target for the company in a research note on Monday, July 15th. Pareto Securities raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Monday. Deutsche Bank lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 price target for the company. in a research note on Thursday, June 20th. Barclays raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $51.85 price target for the company in a research note on Tuesday, June 11th. Finally, Credit Suisse Group raised Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research note on Monday, April 29th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $111.58.

NVO opened at $48.89 on Wednesday. The company has a market cap of $119.73 billion, a price-to-earnings ratio of 19.40, a PEG ratio of 2.23 and a beta of 0.60. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 0.07. The stock’s fifty day moving average is $49.64. Novo Nordisk A/S has a fifty-two week low of $41.23 and a fifty-two week high of $52.83.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Story: How to Invest in the Dividend Aristocrat Index

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.